Blog

News

404

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
Commentary on Protein-Protein and Protein-Peptide Interactions, peptidomimetics and related topics in drug discovery.

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company.

Read Full Press Release

Scroll to top
en_USEnglish